Wiseek

Wiseek scans SEC filings in real time,
analyzes them, and delivers instant insights on market-moving events.
Join Wiseek and be among those who see what matters

[Wiseek @Wiseekai]

Thousands of SEC filings and headlines hit the market every day. We read all of it, score every event 1 to 10, and only the handful that matter reach your feed.

Here is Wiseek in 80 seconds.

[Wiseek @Wiseekai]

The receipts. What Wiseek said the minute each one crossed, and the paper trail.

$MRNA, Jul 31, 7:00 AM ET, scored 8/10 negative at $55.49
Wiseek's take: https://t.co/lEYsifxHu2
The 10-Q: https://t.co/D8lwZP1whj

$MRNA, Aug 5, 10:16 PM ET, scored 8/10 positive at $56.40
Wiseek's take: https://t.co/wMEp7g9OsG

$MRNA, Aug 19, 6:45 AM ET, scored 9/10 at $63.01
Wiseek's take: https://t.co/G25Ir7sbUz

$MRNA, Sep 1, 4:37 PM ET, the $3B 0% convertible
Wiseek's take: https://t.co/UN3vlc2ZfX
The 8-K: https://t.co/A1dK8nQ7m3

$DVLT, Aug 19, 6:01 AM ET, scored 9/10 negative at $0.36
Wiseek's take: https://t.co/YzSbIOLPfM
The 8-K: https://t.co/UPbsEVeDAL

$DVLT, Aug 19, 5:11 PM ET, the 10-Q: $1.4M of cash against $80M burned in six months
Wiseek's take: https://t.co/UqPkREeTS7
The 10-Q: https://t.co/1dbNEFJWBe

The next one is already on the feed: https://t.co/FKuJlgC1jh

[Wiseek @Wiseekai]

One morning. Two filings. Opposite directions.

6:45 AM, Aug 19. Wiseek scored a $MRNA headline 9/10 at $63.
Close: $174.38. Up 177% in one session.

6:01 AM, same morning. $DVLT filed a $25M convertible note.
Wiseek read the terms. 9/10, negative, at $0.36.
The lender converts at 92% of the lowest price of the prior 7 days.
Sep 9 close: $0.21. Down 42%.

The part most people missed: Moderna then borrowed $3B at 0% interest.
Nobody lends $3B for free. The lenders were paid in a right to convert at $210.58.

Receipts, with timestamps. Sources in the first reply.

[Wiseek @Wiseekai]

The receipts. What w esaid the minute each one crossed, and the paper trail.
$BLZE, Jun 23, 8:28 AM ET, scored 9/10 at $7.87
Wiseek's take: https://t.co/9FBwsvHczO
The 8-K: https://t.co/LnQExbdvHX

The line most people skipped: Backblaze handed CoreWeave warrants on 4,194,876 shares at $7.60. The customer took equity in its own supplier. That registration was filed yesterday:
https://t.co/t1oLViMn4t

$BLZE, Aug 3, 4:18 PM ET, scored 9/10 at $17.73
Wiseek's take: https://t.co/M0VfxhZYnf

$AHCO, Aug 4, 7:58 AM ET, scored 9/10 negative at $7.90
Wiseek's take: https://t.co/ZoVx0AaMNH
The 8-K: https://t.co/vKzyxyzpOF

The next one is already on the feed: https://t.co/FKuJlgC1jh

[Wiseek @Wiseekai]

We scored $BLZE a 9 three times.

May 4, after the close: $5.81.
June 23, premarket: $7.87.
Last night, after the close: $17.73.

This morning it opened at $20.13. Up more than 240% from the first score.

The one that mattered was June 23. Backblaze signed a $335M storage deal with CoreWeave, the AI compute company. Backblaze was worth $487M that morning. One customer had just committed to pay it nearly 70% of the entire company.

And the other direction, this morning: $AHCO cut full year revenue guidance by $600M. Scored 9 negative at $7.90, opened at $6.68.

[Wiseek @Wiseekai]

The receipts. What Wiseek said the minute each one crossed, and the paper trail.

$TCX, May 7, 5:01 PM ET, scored 9/10 NEGATIVE at $16.23
Wiseek's take: https://t.co/V2YWqb1pQ1
The 10-Q: https://t.co/m5861SHi7Q

$TCX, Jul 30, 5:05 PM ET, scored 9/10 POSITIVE at $10.40
Wiseek's take: https://t.co/fedZeTxvq7
The 8-K: https://t.co/avmZUP3nY9

Why would anyone let go of a 150 million dollar claim for 3 million? It was a stake in Ting, not in Tucows, and it ranked behind the bank. In a wind down it was probably worth nothing.

The next one is already on the feed: https://t.co/FKuJlgC1jh

[Wiseek @Wiseekai]

$TCX paid 3 million dollars to erase an obligation carrying 150 million.

The filing landed at 5:05 PM on a Thursday, after the close. By Friday's close the stock was up 59%.

And this was the second time Wiseek scored it a 9. The first was in May, a warning about that same obligation, at $16.23. The stock fell 47% to $8.57.

Same company. Same engine. Both directions.

[Wiseek @Wiseekai]

The receipts. Each one: what Wiseek said the minute it crossed, and the paper trail.

$REPL, Jul 30, 5:27 PM ET, scored 9/10 at $5.41
Wiseek's take: https://t.co/1SSaNzmF2e
The company's 8-K on the vote: https://t.co/AQ8IpV7yNt

$MYGN, Jul 30, 4:27 PM ET, scored 9/10, negative, at $3.95
Wiseek's take: https://t.co/m8gUEM95wG
Q2 8-K: https://t.co/8DuFcleJxZ

The next one is already on the feed: https://t.co/FKuJlgC1jh

[Wiseek @Wiseekai]

One Thursday evening. Two headlines, an hour apart.

5:27 PM ET: the FDA panel backs $REPL's melanoma drug 10 to 3, two days after staff notes had cut the stock nearly in half. Wiseek scored it 9/10 at $5.41. Friday it opened at $11.38. Up 107% overnight.

4:27 PM ET: $MYGN misses Q2 and slashes its 2026 outlook. Scored 9/10, negative, at $3.95. Friday close: $2.86. Down 27%.

Same evening. Same engine. Both directions.

[Wiseek @Wiseekai]

The receipts. Each one: the raw filing, and what Wiseek said the minute it crossed.

$FBRX, Jul 9, scored 9/10 at $21.99
Filing: https://t.co/8vNWbpOKVZ
Wiseek's take: https://t.co/RADIwUVIBg

$FBRX, Jul 27, the buyout, scored 10/10
Filing: https://t.co/E8CE8nQCDu
Wiseek's take: https://t.co/cRG4KjkDNv

$CMTG, Jul 29, scored 9/10, negative, at $1.99
Filing: https://t.co/87RDBOV8Py
Wiseek's take: https://t.co/4Lw6XQG7v6

[Wiseek @Wiseekai]

Two stocks. Two scores. Opposite directions.

Jul 9, 8:05 AM ET: $FBRX files an 8-K. Phase 1b hit. Wiseek scored it 9/10 the minute it crossed, at $21.99. Jul 27: bought out at $77 a share. Up more than 250%.

Jul 29, 4:11 PM ET: $CMTG files Q2. Net loss $255.4M, book value down 20%. Scored 9/10, negative, at $1.99. It is $1.77 now.

Not predictions. Receipts, with timestamps.

[Wiseek @Wiseekai]

Join us : https://t.co/i40AIrcalX

[Wiseek @Wiseekai]

Thousands of SEC filings and headlines hit the market every day. We read all of it, score every event 1 to 10, and only the handful that matter reach your feed.

Here is Wiseek in 80 seconds.

[Wiseek @Wiseekai]

https://t.co/TeatLxV7vS

[Wiseek @Wiseekai]

https://t.co/0bANZG3VMm

[Wiseek @Wiseekai]

https://t.co/LI2PtxzyOG

[Wiseek @Wiseekai]

$BAND +23% today after the 10-K dropped at 7:39 AM with an $80M buyback authorization.
That buyback is ~20% of the entire float, authorized at near 52-week lows.
Shareholders just got told management thinks the stock is materially undervalued.
Watch the net loss widening: $(12.9M) in 2025 vs $(6.5M) in 2024. The story depends on what's underneath.

[Wiseek @Wiseekai]

https://t.co/h8uH8ocfz9

[Wiseek @Wiseekai]

Hi Wiseeks 👋
​Top Movement Alert

​$BNAI is seeing massive gains today, Jan 21, 2026, following our latest article.

​What happened with this stock:

​Brand Engagement Network ($BNAI) secured a $2.05M AI licensing deal for Africa, gaining both equity and revenue share. We identified this with a Positive Sentiment and an Importance rating of 9.

​Perfect article in action:

- ​Price when we published: $6.11
- ​Real-time Price: $8.25
- ​Movement: +35%
​See the full article here:
https://t.co/YepRmWmcvM
​#BNAI #StockMarket #AI #Investing #Wiseek

[Wiseek @Wiseekai]

Hi Wiseeks! 👋
Top Movement Alert! 🚀
$CRVS is absolutely exploding today, Jan 20, 2026, following the publication of our latest article!
What happened: Corvus Pharma ($CRVS) just released strong Phase 1 results for Soquelitinib in Atopic Dermatitis, officially advancing the drug to Phase 2. The market is reacting in a big way!
Price at Filing: $10.72
Real-time Price: $20.75 📈
Movement: +94% and climbing!
This is perfect DD in action, identifying the movement exactly when it matters most. ��
Check out the full breakdown here:
https://t.co/0ssHJWwJrr
#CRVS #StockMarket #Biotech #Investing #Wiseek

[Wiseek @Wiseekai]

Hi Wiseeks,

A real time filing moment with $IBRX that shows why speed and clarity matter.

When
• Jan 14, 2026: 8-K filed, breakdown published immediately
• Jan 15, 2026: follow up 8-K filed, feed updated again
What the filing covered
• Saudi regulatory approvals for ANKTIVA in lung cancer
• Approval for ANKTIVA plus BCG in BCG unresponsive non muscle invasive bladder cancer
• Expansion plans across the Middle East and North Africa through regional presence and partnerships
Why this matters
• Filings are public, but the window is short
• Most people see the move first, then go searching for the “why”
• Real time context flips that, you understand the story as it forms

Sources
• SEC filing: https://t.co/lGdNY1wSiZ
• Full breakdown: https://t.co/oiF1dvfr7k
Disclaimer
• Wiseek is an informational product only
• No price forecasts
• No trading signals
• No investment advice
• All insights are for informational purposes only and are based solely on official SEC filings and publicly available SEC data
• Always do your own research and consult a qualified professional before making any investment decision